

January 4, 2021

British Columbia Securities Commission

701 West Georgia Street
Vancouver, B.C.
V7Y 1L2

Dear Sirs/Mesdames:

Re: HAVN Research Inc. (the “Company”).

We refer to the short form prospectus of HAVN Life Sciences Inc. dated January 4, 2021 relating to the sale and issue of 9,346,000 units for total gross proceeds of \$10,000,220.

We consent to being named and to the use, through incorporation by reference in the above-mentioned short form prospectus, of our report dated November 16, 2020 to the director of the Company on the following financial statements:

- Statement of financial position as at July 31, 2020; and
- Statement of loss and comprehensive loss, statement of changes in shareholders' equity, and statement of cash flows for the period from incorporation on March 4, 2020 to July 31, 2020, and a summary of significant accounting policies and other explanatory information.

We report that we have read the short form prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the short form prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



CHARTERED PROFESSIONAL ACCOUNTANTS